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Abstract
Inadequate metabolic control predisposes diabetic patient to a series of complications on 
account of diabetes mellitus (DM). Among the most common complications of DM is neu-
ropathy, which causes microvascular damage by hyperglycemia in the lower extremities 
which arrives characterized by a delayed closing. The global prevalence of diabetic neu-
ropathy (DN) was 66% of people with diabetes in 2015, representing the principal cause of 
total or partial lower extremities amputation, with 22.6% of the patients with DN. Matrix 
metalloproteinases (MMPs) are involved in healing. The function that these mainly play 
is the degradation during inflammation that has as consequence the elimination of the 
extracellular matrix (ECM), the disintegration of the capillary membrane to give way to 
angiogenesis and cellular migration for the remodeling of damaged tissue. The imbalance 
in MMPs may increase the chronicity of a wound, what leads to chronic foot ulcers and 
amputation. This chapter focuses on the role of MMPs in diabetic wound healing.
Keywords: MMPs, wounds, diabetic foot
1. Introduction
Diabetes mellitus (DM) is a set of metabolic disorders, characterized by the presence of per-
sistently elevated blood glucose levels caused by a deficiency of insulin production or insulin 
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resistance [1]. Chronic hyperglycemia is related to the appearance of microvascular complica-
tions, knowing as diabetic neuropathy (DN) that compromises the metabolism, inducing the 
formation of end products of advanced glycosylation and reactive oxygen species and reduc-
tion of the elimination of free radicals and endothelial dysfunction with neuronal damage. 
DN is a set of alterations that affect both the sensory and motor fibers as the autonomous sys-
tem. Hyperglycemia is invariably associated with alterations in nerve conduction and the feet 
are highly susceptible to initiate phases of hypoesthesia. Vasomotor control is lost and blood 
flow to the extremity (vasodilation of the veins of the dorsum of the foot) is increased, but this 
flow is channeled into the skin and arteriovenous fistulas in the bone, which can cause hypo-
perfusion in other tissues. When normal capillary reflexes are lost, capillary hypertension of 
dependence and a decreased vasodilatory response to heat occur. Increased blood flow causes 
demineralization and bone osteopenia [2]. The diabetic foot ulcer (DFU) is the most common 
complication of lower limb DM. It is also the most disabling late complication of the disease. 
The World Health Organization (WHO) defines it as “a syndrome in which complications of 
a diverse etiology: neuropathic, vascular and infectious stemming from DM and predisposing 
to the suffering and development of ulcers.”
There are more than 347 million people with DM in the world, of which 66% had DN in 2015, 
representing one of the principal causes of 22.6% total or partial lower extremities amputa-
tion [3]. DFU is considered as the major epidemic disease in the last decade; its etiological 
factors are DN and arterial disease. Neuropathy alone in 46%, ischemia in 12% being the most 
frequent neuroischemia (60%) and no risk factor identified in 12%. About 15% of diabetic 
patients will have ulcers in the lower extremities, half of these patients who have a single 
ulcer will subsequently develop another ulcer, and one third of these ulcers will cause limb 
amputation [4]. The worldwide DFU prevalence ranges from 1.3% to 4.8%. The current medi-
cal treatments for these chronic wounds continue to be somewhat opposed according to the 
country and the international guides that govern [5]. Part of the affections that these ulcers 
generate is in the extracellular matrix (MEC), where the matrix metalloproteases (MMP) are 
able to degrade all the components of MEC. The MMPs are indispensable for the healing 
process; among its functions is to eliminate the provisional extracellular matrix and facilitate 
migration to the wound center; they also participate in the remodeling of granulation tissue 
in the control of angiogenesis and the release of some growth factors [6, 7]. Different types of 
MMP expression patterns are present in a wound; it has been shown that immunity processes, 
such as cell migration, participate in the process of re-epithelialization and in the formation 
of scars [8]. Accordingly, the correct expression and regulation of MMPs are related with the 
healing process and therefore with a successful process of cicatrization.
2. Contents
2.1. Matrix metalloproteinases (MMPs)
The MMPs belong to a family of zinc-containing endopeptidases are calcium depen-
dent, capable of degrading and remodeling the proteins that form the ECM and carry 
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out different biological and physiological functions; they are regulated by hormones, 
growth factors and cytokines [9]. Based on their specificity for the components of the 
MEC, MMPs are divided into collagenases, gelatinases, stromelysins and matrilysins. A 
numeric system has been adapted for the MMPs grouping them according to their struc-
ture and give place to eight different structural classes of MMPs. This system groups in 
five different groups those MMPs that are secreted, and in three groups to those MMPs 
according to their type of membrane, acquiring as MTP-MMP identification [10]. The first 
group of the minimal domain MMPs contains an amino-terminal signal sequence (Pre) 
that directs them to the endoplasmic reticulum, a propeptide (Pro) with a thiol group 
(SH) that interacts with the zinc and maintains them as inactive zymogens and a catalyst 
with a zinc binding site (Zn). The second group in addition to a minimal domain also 
contains a hemopexin-like domain that is connected to the catalytic domain by a hinge 
(H), which mediates interactions with the tissue inhibitors of the MMPs. The first and last 
of the four replicates in the hemopexin-like domain are linked by a disulfide bond (S-S). 
The third group of gelatinase-binding MMPs contains inserts resembling fibronectin (Fi) 
type II collagen-binding repeats. The fourth group of MMPs is furin (Fu) secreted and 
contains a recognition motif for serine and Fu type intracellular proteinases between 
their polypeptide and catalytic domains that allow intracellular activation by these pro-
teinases. Within the fifth group is the vitronectin-like insert (Vn). The number group 
is included in membrane MMP (MT-MMP); these are conformed by a carboxy-terminal 
single chain (TM) transmembrane domain, a very short cytoplasmic domain (Cy). The 
seventh group has MMPs that are anchored in glycosylphosphatidylinositol (GPI), and 
within group eight MMP-23 is included, is membrane bound, has an N-terminal signal 
(SA) that targets the cell membrane, and therefore in a type II transmembrane MMP, and 
is characterized by a single domain of cysteine (CA) and immunoglobulin (Ig) [11]. This 
is shown in Figure 1 [11].
In mammalian, MMPs are inhibited by four metalloproteinase tissue inhibitors (TIMPs), 
which are endogenous regulators of MMP family proteins, whose function is to determine 
the influence of ECM, cell adhesion molecules, cytokines, chemokines and growth factors. 
TIMPs are formed by an amino-terminal (N-terminal) domain, which is the inhibition domain 
that binds to the active site of MMPs, and a subdomain C. The capacity of these TIMPs to 
inhibit MMPs is due to the interaction in the N-terminal domain that binds within the cleft of 
the active site of the target MMP. The C-domain has two parallel β strands that are connected 
by an α-helix to two anti-parallel β strands. This structure provides the ability of TIMPs to 
interact with the hemopexin domain of some MMP [12].
There are four TIMP family members: TIMP-1, -2, -3 and TIMP-4; each of its N and C 
domains, in their final position, possess six cysteine residues, which constitute three disul-
fide domains. The N-terminal region is assembled into the catalytic domain of MMPs where 
the action of MMP will be inhibited; in the case of the C region, it binds to the proformas 
of a domain called hemopexin C—in its terminal position for the case of the MMP-2,9 and 
thus binds to a pro-enzyme complex inhibitor. For TIMP-2, this binds specifically to the 
surface of the cell with TIM-1MMP and pro MMP-2, this to carry out the activation of the 
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pro-MMP-2 in a simple way [13]; as consequently, TIMP-2 is an inhibitor that also func-
tions as an activator of MMPs. The four TIMPs can inactivate the already active MMPs, but 
they will not do so with the same effectiveness. MMP-1,3,7 and 9 are inhibited by TIMP-1, 
in the case of TIMP-2 inactive to MMP-2. TIMP-3 is inactivating MMP-2,9 but similarly to 
the ADAM group, finally TIMP-4 inactivates MT1-MMP and MMP-2. Therefore, in regard 
to the function of TIMPs is the regular proteolysis activity and in those functions related to 
the activities of the MMPs [14]. The role of TIMP1 is expressed in mammalian tissues, spe-
cifically in reproductive organs; TIMP2 is constitutively expressed in most tissues, but not 
inducible by growth factors and TIMP3 is expressed in tissues as a matrix protein. TIMP4 is 
expressed relatively in heart, ovary, pancreas, colon and testes [12], where they observed the 
specific expression constitutively or inducible, which is regulated at transcriptional level by 
cytokines and growth factors [15]. It has been proposed to have a relevant role in processes 
including cell proliferation, adhesion and migration and/or apoptosis by cutting bioactive 
molecules that modulate these processes [16]. MMPs modulate biological processes during 
pathophysiological events, such as skeletal formation, angiogenesis, cell migration, inflam-
mation, wound healing, coagulation, pulmonary and cardiovascular diseases, arthritis and 
cancer. They have been identified in human degrading components of ECM, cellular recep-
tors and cytokines [17].
Figure 1. Domain structure of MMP groups. All human MMPs show the signal peptide, the pro-domain and the 
catalytic domain. Pre = pre-domain (contains the signal peptide) and Pro = pro-domain, which contains cysteine 
sequence that complexes Zn2+ in the zymogen form. The catalytic region contains the center domain. Fr = furin cleavage, 
Fi = fibronectin repeat, Vn = vitronectin-like insert, Cy = cytosolic, CA = cysteine array, Hemopexin = hemopexin domain, 
IgG-like = Ig-like domain, TM = transmembrane domain and GPI = glycosylphosphatidylinositol anchor. The hemopexin 
domain is linked to the catalytic center by a hinge region.
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2.2. Regulation of MMP activity
In normal physiological conditions, the activity of MMPs is accurately regulated at four 
levels. (1) Transcription. The transcription of MMPs is induced by various exogenous 
signals, including cytokines, growth factors, chemical agents, physical stress and onco-
genic cellular transformation, and also by cell-matrix and cell-cell interactions. The genes 
that control MMPs respond to extracellular signals (MMP-1, MMP-13, MMP-3, MMP-10, 
MMP-7, MMP-12 and MMP-9), which possess an AP-1 (activator of the protein-1) in the 
promoter proximal to the position −70 of the site of initiation of the transcription [18, 19]. 
The promoter regions of the MMP-2 and MMP-11 genes do not contain an AP-1 element 
[20]. The promoter region of membrane type 1-matrix metalloproteinase (MT1-MMP) 
gene lacks of AP-1 element, but it contains Sp-1 binding site which is essential for MT1-
MMP transcription [21]. (2) Activation of precursor zymogens. For the regulation of MMPs 
by a zymogen, a biochemical change is required to turn an inactive enzyme into an active 
enzyme. Propeptides that maintain MMPs in their zymogen form (proMMP) can be acti-
vated by proteinases or in vitro by chemical agents. Proteolysis is initiated in the exposed 
region between the first and second propellants of a propeptide, following the specificity 
of the region followed by the sequence in each MMP. After the initiation of proteolysis, 
a part of the propeptide is separated; this unbalances the rest of the propeptide, includ-
ing the cysteine-zinc interaction and allows the intermolecular process that is carried out 
by activated MMP mediators [22]. Plasmin is generated from the plasminogen by means 
of the tissue plasminogen activator, which is bound to fibrin and to a urokinase activa-
tor attached to the cellular receptor. Plasminogen being the plasminogen enhancer of the 
urokinase is bound to the membrane, generating pro-MMP activation such as proMMP-1, 
3,7,9,10,13 and ECM movement [23]. (3) Interaction with specific components of ECM. The 
location, action and specificity of the MMPs generate an association with the components 
of the NDE. One of the functions of MMPs may be the destruction of ECM in tissues. The 
ECM has the function of storing active biological molecules as they are growth factors [11]. 
For example, the degradation of type I collagen by collagenase is associated with osteo-
clast activation and keratinocyte migration during re-epithelialization [24]. (4) Inhibition 
by TIMPs. TIMPs are specific inhibitors that bind MMPs in a 1:1 stoichiometry and their 
expression is regulated during development and tissue remodeling. Under pathological 
conditions associated with unbalanced MMP activities, changes of TIMP levels are con-
sidered to be important because they directly affect the level of MMP activity. TIMPs are 
specific inhibitors that bind MMPs in a 1:1 stoichiometry; their expression is regulated 
during development and tissue remodeling. Under pathological conditions associated 
with unbalanced MMP activities, changes of TIMP levels are considered to be important 
because they directly affect the level of MMP activity. The proteolytic activity of MMPs is 
inhibited specifically by TIMPs and by nonspecific proteinase inhibitors, such as a 1-pro-
teinase inhibitor and α2-macroglobulin. TIMPs are the major endogenous regulators of 
MMP activity in tissue, which are expressed by different cell types, including fibroblasts, 
keratinocytes, endothelial cells and osteoblasts. As inhibitors of MMPs, TIMPs maintain 
the balance between the ECM deposition and degradation in physiological and pathologi-
cal processes [22].
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2.3. Wound repair
Wound repair is a physiological event, in which tissue injury results in a repair process that 
finally leads to restoration of structure and function of the tissue [25]. During wound healing, 
the degradation of the components of the ECM by MMP is necessary to remove and rear-
range the provisional matrices and allow cell migration [26]; thus, basal keratinocytes are the 
predominant source of MMP. Cutaneous wound repair can be divided into three overlap-
ping phases: (i) formation of fibrin clot followed by inflammation, (ii) re-epithelialization and 
granulation tissue formation and iii) matrix formation and remodeling [27].
2.3.1. Formation of fibrin clot followed by inflammation
The first step for wound repair is a fibrin clot formed through platelet aggregation and blood 
coagulation. The coagulation cascades are initiated by coagulation factors of the injured skin, 
this by means of the extrinsic system. The thrombocytes are activated to generate aggrega-
tion by means of exposed collagen, this being controlled by the intrinsic system. Following 
this, the injured vessels continue with a vasoconstriction of 5 or 10 minutes, being triggered 
by platelets; this to reduce blood loss and begin to fill the void of tissue that was generated 
by the wound through a compound clot cytokines and growth factors [28]. Vasoconstriction 
generates clots, followed by vasodilation, where thrombocytes invade the wound matrix on a 
provisional basis [27]. The formed clot contains fibrin molecules, fibronectin, vitronectin and 
thrombospondin, forming the provisional matrix as a scaffold structure for the migration of 
leukocytes, keratinocytes, fibroblasts and endothelial cells [29]. Platelets influence leukocyte 
infiltration; this is mediated by the synthesis of factors for chemotaxis. Platelets and leuko-
cytes release cytokines and growth factors for activation of the inflammation process. The 
interleukins IL-1α, β, IL-6 and TNF-α are involved, such as FGF-b, IGF, TGF-β are involved 
in the process of collagen synthesis, factors such as FGF-B, VEGF subunit A, HIF-1 and TGF-β 
are involved for angiogenesis and for the EGF, FGF-b, IGF, TGF-α [30]. See Figure 2.
2.3.2. Proliferation and re-epithelialization
In the proliferation phase, the main focus of the healing process is to cover the wound surface, 
to form granulation tissue and to restore the vascular network. After to tissue injury, plate-
lets are recruited to the injury site to stop the bleeding. Platelets also release platelet-derived 
growth factor (PDGF) that initiates the migration of neutrophils and macrophages, in addi-
tion to causing the synthesis of growth factors and related cytokines in wound healing [31]. 
This factor is also involved in the stimulation of collagenase and in fibroblastic cell of human 
skin, with MMP-8 being more frequent in tissue damage [18]. The MMP-1,2,3,9 are synthe-
sized by platelets; the function of MMP-1,2 aid in the balance of platelet adhesion and the con-
glomeration thereof [27]. In the inflammatory process, cells such as neutrophils are involved 
in the wound to protect infections and generate the synthesis and stimulation of MMP-8, 
being necessary for wound debridement and division of damaged type I collagen; the MMP-9 
also participates by separating the collagen types that also participate (IV, V and X) [5].
Through the control of regulatory cytokines such as IFN-γ and TGF-β, the synthesis of col-
lagen, fibronectin and other basic substances necessary for the healing of fibroblast wounds 
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represents the basis for the new connective tissue matrix. Therefore, the migration of local 
fibroblasts along the fibrin network and the initiation of re-epithelialization from the wound 
edges, neovascularization and angiogenesis are activated by capillary sprouting [27]. This 
process is activated by signaling pathways of epithelial and non-epithelial cells at the wound 
edges, which release a myriad of different cytokines and growth factors such as EGF, KGF, 
IGF-1 and NGF [30].
In the process of re-epithelialization participate, the laminin is a component basal of the epi-
thelium and plays roles in cell adhesion, migration, proliferation, differentiation and angio-
genesis. There are 15 isoforms of laminin, of which laminin-5 is specific to epithelial cells. 
Laminin-5 has been shown to promote keratinocyte migration and induction of MMP-9; cell 
motility depends on MMP-9 activity, indicating that MMP-9 plays a role in re-epithelializa-
tion [32]. It is known that MMP-2 and MMP-14 cleave laminin-5 [33, 34] generating a fragment 
that binds to the epidermal growth factor receptor (EGF), which stimulates cell migration. 
The released FGF-2 from macrophages binds to heparan sulfate, which induces the growth of 
fibroblasts and endothelial cells [30]. Platelets and macrophages release vascular endothelial 
growth factor (VEGF), stimulating proliferation and migration of endothelial cells, as well as 
keratinocyte migration where are involved the MMP-1, MMP-2, MMP-9, and MMP-13 this 
plays a critical role in wound healing [35, 36].
2.3.3. Matrix formation and remodeling
Remodeling is the last phase of wound healing and occurs from day 21 to 1 year after 
injury. The collagen synthesis increases throughout the wound, whereas fibroblast pro-
liferation decreases successively, adjusting a balance between synthesis and degradation 
Figure 2. Wound repair phases. The wound repair phases involve: 1. Formation of the clot. The fibrin clot is 
being formed through platelet aggregation, coagulation cascades, fibrin molecules, fibronectin, vitronectin and 
thrombospondin to form a temporary scaffold for the initiation of leukocyte, keratinocyte, fibroblast and endothelial 
cell migration. 2. Proliferative phase. The platelets initiate the synthesis of MMPs 1, 2, 3, 9; MMP-1 and MMP-2 
generate a balance in the adhesion of platelets and secrete PDGF initiating the migration of neutrophils, macrophages 
and growth factors. This generates the stimulation of different types of collagen, which are separated with the help of 
MMP-9. This stimulation of collagen is given by fibroblastic cells to begin the healing process and cover the surface 
of the wound. 3. Remodeling phase. In the remodeling of granulation tissue, there is an increase in the synthesis 
of collagen generating a decrease in fibroblasts. The keratinocytes initiate their migration to the clot through the 
granulation tissue to initiate tissue repair.
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of ECM [37]. This shows a signal. It gives a retraction and reorganization of filaments 
in the intracellular tone towards cell migration, where the keratinocytes migrate into 
the fibrin clot by infiltrating the upper layers of the granulation tissue [38]. The onset of 
granulation tissue repair is stopped by apoptosis, since in an old wound it is character-
ized by the absence of vascular structures within it and by having only ECM and having 
absence of cells [39]. In the case of maturation of a wound, type III collagen is displaced 
by collagen type I [40]. In the early stages of the remodeling phase, the provisional wound 
matrix contains predominantly fibrin and fibronectin, which are subsequently replaced 
by proteoglycan and collagen type I and III molecules, increases the tensile strength of 
the scar matrix. Fibroblasts are stimulated to transform into myofibroblasts that contract 
the wound matrix. At the end of the remodeling stage, the high density of blood vessels 
and myofibroblasts decrease with apoptosis. At the end of the process, the wound is com-
pletely closed [41, 42].
2.4. Proteolysis in wound repair
The proteolytic degradation of ECM is necessary in many stages of wound repair, such as 
interim matrix degradation, angiogenesis, keratinocyte migration and remodeling of granula-
tion tissue ECM [43]. MMP-28 and MMP-19 are found in keratinocytes in the basal strata and 
suprabasals of healthy skin in an in vivo model [44]; in addition, MMP-19 is also found in hair 
follicles, endothelial cells and in veins and arteries [45]. In some wounds, the basal membrane 
is destroyed; this lesion temporarily retains MMP-1 expression in migratory cells that are 
expressed in the dermis, such as keratinocytes, with absence of a basement membrane [46]. 
The synthesis of MMP-1 is paramount for the initiation of re-epithelialization, so keratino-
cytes bind with type I collagen. Native type I collagen is known to generate MMP-1 synthesis 
in cells in vitro, contrary to basement membrane proteins such as fibronectin or collagen type 
III that do not generate this synthesis of MMP-1 [47].
MMP-1 is important in the process of migration of keratinocytes into native type I colla-
gen and its synthesis, which is being generated by α2β1 integrin [24]. In humans, the α2β1-
MMP-1 complex is to function as a motor stimulating migration of keratinocytes on type I 
collagen during re-epithelialization. Subsequent to the initiation of re-epithelialization, a new 
basement membrane is generated; here, the expression of MMP-1 in epidermis is arrested by 
cellular junctions with basement membrane proteins [47]. The role of MMP-1 in the wound 
healing process has been demonstrated in murine models, where there has been a delay in 
total wound [48].
Collagenase-3 (MMP-13) has been found in human skin, and it is related to the role of wound 
healing in the dermis. MMP-13 is synthesized by fibroblasts in those human cutaneous fetal 
wounds [49]. MMP-1 and MMP-13 can also regulate the survival of fibroblasts during der-
mal wound healing (affecting fibroblasts), which is mediated by matrix shrinkage and matrix 
rigidity [50]. MMP-8 is expressed by neutrophils, being stored in the cellular granules and 
being secreted to the outside by the activation thereof. In excessive skin wounds, the MMP-8 
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is overexpressed [52]. Some experimental models in MMP-13-deficient knockout mice dem-
onstrate that there is a MMP-13 compensation for MMP-8, demonstrating a delay in wound 
healing due to impaired re-epithelialization, low level of infiltration of neutrophils and a per-
sistent inflammatory syndrome [51, 52].
The stromelysins, MMP-3 and MMP-10, are expressed by epidermal cells during wound 
repair in human and mouse wounds. MMP-3 is expressed by the basal proliferating kera-
tinocytes behind migrating cells, whereas MMP-10 migration occurs by keratinocyte leaf 
[53]. MMP-3 can destroy substrates of the ECM, basement membrane proteins, in addition 
to increasing the activity and availability of cytokines and growth factors such as FGF-b and 
HB-EGF [22]. This poses a role for MMP-3 in the organization of the new basement membrane 
and in the involvement of cell migration and proliferation. The remodeling of the basement 
membrane after re-epithelialization, and degradation of the fibrin containing the provisional 
matrix, MMP-9 may be involved in the final adjustment of the epidermal tissue after wound 
healing by remodeling the cell [54].
MMP-2, 9, MT1-MMP and MMP-19 are synthesized in endothelial cells [55, 56]. Within these, 
MMP-2 and 9 have key participation in physiological aspects such as those tumorigenic and 
angiogenic processes [57]. These MMPs are responsible for degrading components of the 
vascular basement membrane, which is essential for the generation of new blood vessels. 
These MMPs physiologically participate in the activation of growth factors and cytokines 
related to angiogenesis [30]. MT1-MMP when involved in the generation of blood vessels is 
related to fibrinolytic and collagenolytic activity to generate invasion of these new vessels 
by crossing fibrin barriers in the stroma of damaged tissue [58]. MMP-19 is involved in the 
proliferation of epithelial tissue, endothelial cells, fibroblast cells and microvascular cells in 
macrophages [59]. See Figure 2.
2.5. MMPs in chronic wounds
Chronic wounds are defined as wounds where healing is delayed due to one or more factors. 
Depending on the etiology, a wound is considered to be chronic if it is still present after 4–6 
weeks [60]. Such wounds may from the outset show chronic features, for example leg ulcers, 
pressure ulcers (PUs), DFUs and amputation stumps, or may initially be acute in nature (such 
as surgical wounds and traumatic wounds) and become chronic after several weeks of stag-
nation due to the patient’s general condition or inappropriate care; they may last for several 
months or years.
The MMPs implicated in the wound healing process are listed in Table 1.
Chronic wounds present higher levels of protease activity than acute wounds. This has been 
demonstrated through comparative trials analyzing MMP levels in different populations. 
Chronic wounds, including venous leg ulcers (VLUs) [40, 61, 62], DFUs [63, 64], PUs [65] 
dehiscent surgical wounds and acute wounds that have become chronic, were found to have 
elevated MMP activity.
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There is evidence that associates DM to changes in the foot structure, including abnormalities 
in fiber structure and organization, increased tendon thickness, volume and a tendency of 
impairing biomechanical properties [66]. Interestingly, these alterations may represent fea-
tures of the ECM, which is in a constant state of dynamic equilibrium between synthesis and 
degradation. Besides the relevance of MMPs in the ECM and their role in the pathophysiol-
ogy, data linking these proteases to the development and progression of diabetic disorders 
are still scarce. It has been found strong expression of MMP-13 and MMP-3 in diabetic foot 
ulcer both in diabetic and healthy, whereas MMP-13 expression was upregulated and MMP-3 
expression decreased in the diabetic ulcer healing model. Moreover, upregulation of MMP-9 
and MMP-13 and increased enzymatic activity of MMP-9 in a model in vitro treated with high 
glucose concentration is found [67].
As a result, it was obtained that at high glucose concentrations collagen degradation is 
induced by overproduction of MMPs, which leads to a vulnerable tissue [68]. Adding the 
MMPs also to the process of generation of diabetic fibrosis, this being a pathology differen-
tiated by the excess of MMPs in the ECM generating changes in the same. This is a result of 
an imbalance between MMPs and TIMPs activity tissue such as hyperglycemia, dyslipid-
emia and hypertension [69], but increased production of collagen and other ECM compo-
nents may also be involved. In fact, recruitment of inflammatory cells have been connected 
to dysregulation of homeostasis fibroblasts followed by secretion of ECM proteins, which 
results in an increased turnover and remodeling of the ECM. Moreover, MMPs are able 
to increase release of TGF-β1, which results in fibroblast cell proliferation and collagen I 
Type of MMPs Subgroup of MMPs Metalloprotease
Soluble gelatinases Gelatinases MMP-2: Gelatinase-A
MMP-9: Gelatinase-B
Archetypal MMPs Collagenases MMP-1: Collagenase-1, interstitial 
collagenase
MMP-8: Collagenase-2, neutrophil 
collagenase
MMP-13: Collagenase-3
Metalloelastase MMP-12
Stromelysins MMP-3: Stromelysin-1
MMP-10: Stromelysin-2
MMP-11: Stromelysin-3
Matrilysins Matrilysins MMP-7: Matrilysin
MMP-26: Matrilysin-2
MMP, matrix metalloproteinase.
Table 1. The main MMPs is involved into the wound healing process.
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degradation [70]. Therefore, the relationship between MMP/TIMP may be associated with 
the development of diabetic ulcer as a consequence of poor regulation of ECM [69]. It is 
known that during DM there is no efficient wound healing; this being a consequence of the 
complications that occur in the metabolism and being a greater production of gelatinases in 
diabetes as a result of a period of inflammation [71]. MMPs are present in the degradation 
of the ECM, but also participate in the recovery of the trauma and promoting the renewal 
of the tissue. Likewise, the relationship with collagen is involved in the pathogenesis of the 
diabetic ulcer, implying poor tissue regeneration through a decrease in MMP-3 [71].
2.6. MMP levels in diabetic wound healing
Persistent hyperglycemia in the blood of diabetic patients induces the majority of the micro- 
and macrovascular complications associated with DM [20] and increases MMP activity 
directly or indirectly through oxidative stress or advanced glycation end products (AGEs) 
[72, 73]. An increased activity of MMPs may initiate the development of diabetic periph-
eral arterial disease. Hyperglycemia affects the regulation of MMP/TIMP and increases the 
activities of MMP-1, MMP-2 and MMP-9 in vascular cells, stimulating the degradation of the 
ECM and causing an imbalance in diabetes [74]. An increase in expression of MMP-2 and 
MMP-9 as well as protein expression of TIMP-1 may be a resulting factor in impaired wound 
healing and might provide an explanation for human arterial vasculature in type 2 DM [73].
The significantly higher levels of MMP in patients with metabolic syndrome as compared 
with normal individuals indicate that such patients may have high tendencies of developing 
other physiological problems [75]. The process of wound healing necessitates ECM degra-
dation to be controlled; thus, an imbalance between ECM formation and the degradation 
process could lead to the development of chronic ulcers or fibrosis [76]. Cellular and bio-
chemical imbalances, tissue damage, or other disease conditions may present varied effects in 
the healing process. This also upsets the proteases, cytokines, and growth factors leading to 
an absence or delay of wound closure preventing successful skin repair [72].
Enzyme activity affected by hyperglycemia disrupts the expression of MMPs in diabetes, 
and this generates an increased proteolytic environment provoked by an alteration in MMPs 
and TIMPs that affects patients with diabetic ulcers [77]. In healthy tissues, the levels of 
MMPs and TIMP are low; however, their synthesis and the activation of these are stimulated 
at the time of the remodeling of a tissue. In healthy skin, only the constitutive MMP-3, 7, 19, 
28 and TIMP-1 expression has been documented [78]. Increased levels of MMP-1, MMP-8 
and MMP-9 have been associated with a slow epithelial regeneration to heal wounds, with 
relatively low TIMP levels. MMP-9 degrades fibronectin into fragments, which further 
activates MMP, cell migration and proliferation. This provokes white blood cell infiltra-
tion, tissue damage and continuous inflammation. MMP-1, MMP-8 and MMP-9 are highly 
expressed in venous wounds in the absence of TIMPs [79, 80]. In addition, overexpression 
of MMP-9 and MMP-2 has been found in serum of patients with metabolic syndrome. The 
altered expression of MMPs may provoke pathogenesis in several tissues [75, 81]; the altered 
gene expression in MMP-9 is a cause of non-healing diabetic ulcers, being augmented in 
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diabetic patients and not found in healthy patients [52], and MMP-1, MMP-2, MMP-8 and 
MMP-9 were highly expressed in normal and chronic diabetic wounds with a decrease in 
TIMP-2 [63]. This could be due to high proteolytic surroundings promoting poor healing in 
diabetes. Similarly, there was an overexpression of MMP-1 and MMP-9, as well as TIMP-1, 
in keratinocytes derived from foot ulcers in diabetic type 1 patients, supporting the theory 
on the upregulation of MMPs and TIMPs in diabetic foot ulcers [78]. Increased expression of 
MMP-9, TNF-α and other growth factors in DFUs has been found and concluded that they 
could be linked with slow-to-heal ulcers in diabetics and therefore a target for new thera-
peutic management [71].
Ascertained that MMPs and TIMPs are elevated in chronic wounds; however, they may also play 
a role in determining the level of chronicity. Yadav et al. [75] elucidated that chronicity is associ-
ated with an increase mainly in MMP-9 and MMP-8 and elastase activity that may eventually 
alter collagen synthesis and the release of growth factor and cytokines into the site of injury [82].
2.7. MMPs, prediction and healing in DFUs
MMPs are associated with wound healing. Investigating its expression in chronic wounds 
helps to generate a better evaluation in the prognostic aspect for diabetic foot ulcers; in this 
way, this knowledge assists in the investigation of aspects for the inhibition of these. DFUs 
often fail to heal, and the mechanism is not well explained. Normal wound healing is a com-
plex process involving a highly orchestrated cascade of events that include hemostasis, inflam-
mation, proliferation, angiogenesis and remodeling. In each of these events, the ECM interacts 
with growth factors and cells. Delayed healing is characterized by an increase in MMPs and 
a decrease in the levels of TIMPs and growth factors (specifically transforming growth factor 
TGF-β). MMPs and TIMPs are synthesized by cells associated with wound healing, where their 
concentrations vary according to the stage of healing in which the wound is found [83, 84].
Investigations on DFU wounds are limited by appearance to obtain tissue biopsies. The 
wounds secrete liquid, which can be obtained in a non-invasive way for the patient, solv-
ing the problem a little for future investigations. The use of wound secretion is supported 
by previous investigations, where a high bacterial count has been demonstrated, and this 
of course resulting in poor wound healing [85]. High concentrations of MMP-9 have been 
demonstrated, giving a prediction that would lead to poor healing in DFU. Although the 
mechanism that generates the increase of MMP-9 is not yet known, it is associated with the 
inflammatory syndrome, since MMP-9 is being synthesized by neutrophils and macrophages 
[86]. It has been found in previous studies that the high bacterial count in the wound despite 
the absence of infection is indicative of poor wound healing [85]. Generating the hypothesis 
about a high bacterial count and high concentrations of MMP is also related to poor healing. 
It has also been demonstrated a statistically significant relationship between the MMP-1/
TIMP-1 and the favorable healing [87]. MMP-1 is the main responsible for healing collage-
nase-related due to the benefit it brings to complete the proliferative phase; this has shown 
that degradation of collagen I is required for keratinocyte migration, which involves re-epi-
dermization [24, 88]. Other studies of MMP have studied the role of MMP-2; however, it is 
not yet clear, due to variations in expression or concentration levels. This proposes the role of 
MMP-2 at least in chronic wounds, because MMP-2 is known to be synthesized by fibroblasts 
that are secreted in the proliferative phase where inflammation predominates [89, 90].
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2.8. MMPs and topical and biologic therapies for DFU
It is reported that the dynamic changes on the content and activity of MMP-2 and/or TIMP-2, 
are secreted by fibroblasts majorly, play much essential parts in the normal healings, espe-
cially during the midterm and later phases, including accelerating revascularization, granu-
lation tissues regeneration as well as the connective tissues reformation and safeguarding 
the normal dermis to some extent [91]. Owning to the decreased content and/or activity of 
growth factors and the disturbed balance of MMPs/TIMPs system, which results in excessive 
solvent activity and then reduced content or damaged structure of the growth factors and 
ECMs, the diabetic cutaneous ulcers are always poorly healed. MMP-2 is found to be exces-
sively generated while TIMP-2 is deficiently secreted in diabetic chronic wounds, and the 
pathologic imbalance may bring about retarded progress of tissue regeneration and revascu-
larization [86]. The efficacy of autologous platelet-rich gel (APG) on refractory wounds in the 
healing mechanism is recognized [92, 93] including upregulating the content of many growth 
factors and releasing antibacterial peptides [94]. Furthermore, in some basic researches, 
TGF-β1 has been reported to inhibit the generation of MMP-2 by depressing its genetic tran-
scription and enhance that of TIMP-2 meanwhile [5]. In preliminary clinical studies, the 
local concentration of TGF-β1 increases after APG treatment [95]. This has been proven and 
reported, where APG treatment may suppress the expression of MMP-2 and promote that of 
TIMP-2 in the diabetic chronic refractory cutaneous wounds and furthermore decrease the 
ratio of the MMP-2/TIMP-2, and TGF-β1 may be related to these effects [96].
The photobiomodulation (PBM) is a noninvasive form of light therapy for wound healing, 
whereby several biological, chemical and cellular processes are stimulated to speed up healing; 
investigations carried out demonstrated PBM to enhance wound healing [97]. The biostimula-
tory effect of PBM in the near infrared (NIR) range modulates wound healing events in various 
cells. This generates an increased collagen activity twofold, increased MMP-2 activity, upregu-
lated MMP-1 and TIMP-2 expression and down regulated MMP-2 and IL-1β [98]. These find-
ings are of therapeutic importance in situations with depleted smooth cells, weakened ECM 
and increased pro-inflammatory markers as major pathological components. The PBM is able 
to alter the expression of MMPs in diabetic wounds and enhance collagen production; how-
ever, experiments done on human skin demonstrated variations in gene expression in the fibro-
blasts [99]. Yadav et al. (2014) found that PBM altered 49 genes involved in the ECM in vitro, 
with genes in a diabetic wounded cell model mostly downregulated, among which were MMP-
1, MMP-2, MMP-8, MMP-12, MMP-14 and MMP-16 [75]. PBM is known for its stimulatory 
effects and promotes MMP activity and gene expression; hence maintaining a dynamic balance 
between the proteolytic activity and degradation could be a target for therapeutic advancement 
[99]. However, its effect on various matrix proteins still needs to be further understood.
3. Conclusions
In the course of the regeneration of a lesion, degradation in the formation of blood vessels is 
necessary, also so that there is adequate cell migration and a proteolysis of the ECM to obtain 
a remodeling of granulation tissue. Consequently, the degradation is under a precise and 
strict control, where the loss of homeostasis between ECM deposition and proteolysis results 
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in a significant failure in wound healing, as occurs in DFUs. MMPs play a significant role in 
tissue remodeling; their role in normal and abnormal wound healing is not well character-
ized. The MMPs are known for degradation of the ECM and have been shown to be upregu-
lated in most pathologies; in the case of DFUs, they have been recognized as predicting and 
its expression may show alterations in the tissues, serum, plasma or fluid of wounds identify 
the mechanisms involved in wound healing and thereby to intervene proactively to prevent 
the normal wound from becoming chronic and later in diabetic ulcer or amputation and if this 
progress may lead to death.
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